[1]
|
Saver, J.L. (2016) Clinical Practice. Cryptogenic Stroke. The New England Journal of Medicine, 374, 2065-2074.
https://doi.org/10.1056/NEJMcp1503946
|
[2]
|
Elgendy, A.Y., Saver, J.L., Amin, Z., et al. (2020) Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke. JAMA Neurology, 77, 878-886.
https://doi.org/10.1001/jamaneurol.2020.0458
|
[3]
|
Teshome, M.K., Najib, K., Nwagbara, C.C., et al. (2020) Patent Foramen Ovale: A Comprehensive Review. Current Problems in Cardiology, 45, Article ID: 100392. https://doi.org/10.1016/j.cpcardiol.2018.08.004
|
[4]
|
Biglane, J.B., Saxon, J., Guild, C., et al. (2015) Thrombus in Transit across the Patent Foramen Ovale. Journal of the American College of Cardiology, 65, 664. https://doi.org/10.1016/S0735-1097(15)60664-7
|
[5]
|
Akagi, T. (2021) Transcatheter Closure of Patent Foramen Ovale: Current Evidence and Future Perspectives. Journal of Cardiology, 77, 3-9. https://doi.org/10.1016/j.jjcc.2020.09.005
|
[6]
|
Nakayama, R., Takaya, Y., Akagi, T., et al. (2019) Identification of High-Risk Patent Foramen Ovale Associated with Cryptogenic Stroke: Development of a Scoring System. Journal of the American Society of Echocardiography, 32, 811-816. https://doi.org/10.1016/j.echo.2019.03.021
|
[7]
|
Radico, F., Foglietta, M., Di Fulvio, M., et al. (2021) The “Dreaded PFO”: Anatomical and Functional Features of High Risk for Stroke. European Heart Journal Supplements, 23, E189-E193. https://doi.org/10.1093/eurheartj/suab119
|
[8]
|
Ueno, Y., Shimada, Y., Tanaka, R., et al. (2010) Patent Foramen Ovale with Atrial Septal Aneurysm May Contribute to White Matter Lesions in Stroke Patients. Cerebrovascular Dis-eases, 30, 15-22. https://doi.org/10.1159/000313439
|
[9]
|
Yang, X., Wang, H., Wei, Y., et al. (2020) Diagnosis of Patent Foramen Ovale: The Combination of Contrast Transcranial Doppler, Contrast Transthoracic Echocardiography, and Contrast Transesophageal Echocardiography. BioMed Research International, 2020, Article ID: 8701759. https://doi.org/10.1155/2020/8701759
|
[10]
|
Johansson, M.C., Eriksson, P., Guron, C.W., Dellborg, M. (2010) Pit-falls in Diagnosing PFO: Characteristics of False-Negative Contrast Injections during Transesopha Contrast Injections during Transesophageal Echocardiography in Patients with Patent Foramen Ovales. Journal of the American Society of Echocardiography, 23, 1136-1142.
https://doi.org/10.1016/j.echo.2010.08.004
|
[11]
|
Jesurum, J.T., Fuller, C.J., Renz, J., et al. (2009) Diagnosis of Secondary Source of Right-to-Left Shunt with Balloon Occlusion of Patent Foramen Ovale and Power M-Mode Tran-scranial Doppler. JACC: Cardiovascular Interventions, 2, 561-567. https://doi.org/10.1016/j.jcin.2009.04.010
|
[12]
|
王浩, 吴伟春, 施怡声, 权欣, 陶瑾. 卵圆孔未闭右心声学造影中国专家共识[J]. 中国循环杂志, 2022, 37(5): 449-458.
|
[13]
|
张玉顺, 蒋世良, 朱鲜阳. 卵圆孔未闭相关卒中预防中国专家指南[J]. 心脏杂志, 2021, 33(1): 1-10.
|
[14]
|
He, D., Shi, Q., Xu, G., et al. (2018) Clinical and Infarction Patterns of PFO-Related Cryptogenic Strokes and a Prediction Model. Annals of Clinical and Translational Neurology, 5, 1323-1337. https://doi.org/10.1002/acn3.647
|
[15]
|
Benvenuti, F., Meucci, F., Vuolo, L., et al. (2022) Heart and Brain Team Ca-reggi University Hospital, Florence, Italy. Relation between the Size of Patent Foramen Ovale and the Volume of Acute Cerebral Ischemic Lesion in Young Patients with Cryptogenic Ischemic Stroke. Neurological Sciences, 43, 453-458.
https://doi.org/10.1007/s10072-021-05330-y
|
[16]
|
Hayashida, K., Fukuchi, K., Inubushi, M., et al. (2001) Embolic Distribution through Patent Foramen Ovale Demonstrated by (99m)Tc-MAA brain SPECT after Valsalva Radionuclide Venography. Journal of Nuclear Medicine, 42, 859-863.
|
[17]
|
穆利英, 付强, 南京, 孟帅, 隋滨滨, 李子孝, 杜丽娟, 鞠奕, 赵性泉, 金泽宁. 卵圆孔未闭相关缺血性卒中的临床和神经影像学特征分析[J]. 中国卒中杂志, 2020, 15(5): 544-549.
|
[18]
|
Wu, X., Klomparens, K., Chen, Z., et al. (2022) Different Patterns of White Matter Lesions among Patent Foramen Ovale, Atherosclerotic Cerebral Small Vessel Disease and Cerebral Venous Thrombosis. Journal of Thrombosis and Thrombolysis, 53, 911-925. https://doi.org/10.1007/s11239-021-02624-y
|
[19]
|
Turc, G., Lee, J.Y., Brochet, E., et al. (2020) Atrial Septal Aneurysm, Shunt Size, and Recurrent Stroke Risk in Patients with Patent Foramen Ovale. Journal of the American College of Cardiology, 75, 2312-2320.
https://doi.org/10.1016/j.jacc.2020.02.068
|
[20]
|
Thaler, D.E., Ruthazer, R., Weimar, C., et al. (2014) Recurrent Stroke Predictors Differ in Medically Treated Patients with Pathogenic vs. Other PFOs. Neurology, 83, 221-226. https://doi.org/10.1212/WNL.0000000000000589
|
[21]
|
Deng, W., Yin, S., McMullin, D., et al. (2020) Residual Shunt after Patent Foramen Ovale Closure and Long-Term Stroke Recurrence: A Prospective Cohort Study. Annals of Internal Medicine, 172, 717-725.
https://doi.org/10.7326/M19-3583
|
[22]
|
Gaspardone, A., Sgueglia, G.A., De Santis, A., et al. (2020) Predictors of Residual Right-to-Left Shunt after Percutaneous Suture-Mediated Patent Fossa Ovalis Closure. JACC: Cardiovascular Interventions, 13, 2112-2120.
https://doi.org/10.1016/j.jcin.2020.06.004
|
[23]
|
Deng, W., McMullin, D., Inglessis-Azuaje, I., et al. (2021) Effect of Patent Foramen Ovale Closure after Stroke on Circulatory Biomarkers. Neurology, 97, e203-e214. https://doi.org/10.1212/WNL.0000000000012188
|
[24]
|
Ozdemir, A.O., Tamayo, A., Munoz, C., et al. (2008) Cryptogenic Stroke and Patent Foramen Ovale: Clinical Clues to Paradoxical Embolism. Journal of the Neurological Sciences, 275, 121-127. https://doi.org/10.1016/j.jns.2008.08.018
|
[25]
|
Alkhouli, M., Sievert, H., Holmes, D.R. (2019) Patent Foramen Ovale Closure for Secondary Stroke Prevention. European Heart Journal, 40, 2339-2350. https://doi.org/10.1093/eurheartj/ehz157
|
[26]
|
Kent, D.M., Saver, J.L., Ruthazer, R., et al. (2020) Risk of Paradoxi-cal Embolism (RoPE)-Estimated Attributable Fraction Correlates with the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials. Stroke, 51, 3119-3123.
https://doi.org/10.1161/STROKEAHA.120.029350
|
[27]
|
Kent, D.M., Saver, J.L., Kasner, S.E., et al. (2021) Het-erogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data from Randomized Trials of Device Clo-sure of Patent Foramen Ovale after Stroke. JAMA, 326, 2277-2286. https://doi.org/10.1001/jama.2021.20956
|
[28]
|
Giannandrea, D., Padiglioni, C., Eusebi, P., et al. (2020) Clinical RoPE (cRoPE) Score Predicts Patent Foramen Ovale Detection among Stroke Patients: A Multicenter Observational Study. Neurological Sciences, 41, 3227-3233.
https://doi.org/10.1007/s10072-020-04386-6
|
[29]
|
Hołda, M.K., Krawczyk-Ożóg, A., Koziej, M., et al. (2021) Pa-tent Foramen Ovale Channel Morphometric Characteristics Associated with Cryptogenic Stroke: The MorPFO Score. Journal of the American Society of Echocardiography, 34, 1285-1293.e3. https://doi.org/10.1016/j.echo.2021.07.016
|
[30]
|
Furlan, A.J., Reisman, M., Massaro, J., et al. (2012) Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale. The New England Journal of Medicine, 366, 991-999. https://doi.org/10.1056/NEJMoa1009639
|
[31]
|
Carroll, J.D., Saver, J.L., Thaler, D.E., et al. (2013) Clo-sure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke. The New England Journal of Medicine, 368, 1092-1100. https://doi.org/10.1056/NEJMoa1301440
|
[32]
|
Mas, J.L., Derumeaux, G., Guillon, B., et al. (2017) Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. The New England Journal of Medicine, 377, 1011-1021. https://doi.org/10.1056/NEJMoa1705915
|
[33]
|
Søndergaard, L., Kasner, S.E., Rhodes, J., et al. (2017) Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. The New England Journal of Medicine, 377, 1033-1042. https://doi.org/10.1056/NEJMoa1707404
|
[34]
|
Saver, J.L., Carroll, J.D., Thaler, D.E., et al. (2017) Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. The New England Journal of Medicine, 377, 1022-1032.
https://doi.org/10.1056/NEJMoa1610057
|
[35]
|
Lee, P.H., Song, J.K., Kim, J.S., Heo, R., et al. (2018) Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. Journal of the American College of Cardiology, 71, 2335-2342.
https://doi.org/10.1016/j.jacc.2018.02.046
|
[36]
|
Nachoski, D., Schroeder, J., Almalla, M., et al. (2021) Dual-Center Experiences with Interventional Closure of Patent Foramen Ovale: A Medium-Term Follow-Up Study Comparing Two Patient Groups Aged under and over 60 Years. Clinical Cardiology, 44, 386-391. https://doi.org/10.1002/clc.23548
|
[37]
|
Wintzer-Wehekind, J., Alperi, A., Houde, C., et al. (2020) Transcatheter Closure of Patent Foramen Ovale in Patients Older than 60 Years of Age with Cryptogenic Embolism. Revista Española de Cardiología (Engl Ed), 73, 219-224.
https://doi.org/10.1016/j.rec.2019.07.003
|
[38]
|
Rohatgi, N., Smilowitz, N.R., Lansberg, M.G. (2020) Perioperative Stroke Risk Reduction in Patients with Patent Foramen Ovale. JAMA Neurology, 77, 1479-1480. https://doi.org/10.1001/jamaneurol.2020.2619
|
[39]
|
Varotto, L., Bregolin, G., Paccanaro, M., et al. (2021) Network Meta-Analysis on Patent Foramen Ovale: Is a Stroke or Atrial Fibrillation Worse? Neurological Sciences, 42, 101-109. https://doi.org/10.1007/s10072-020-04922-4
|
[40]
|
Gevorgyan Fleming, R., Kumar, P., West, B., et al. (2020) Comparison of Residual Shunt Rate and Complications across 6 Different Closure Devices for Patent Foramen Ovale. Catheterization and Cardiovascular Interventions, 95, 365-372. https://doi.org/10.1002/ccd.28527
|
[41]
|
Angelini, F., Fortuni, F., Tsivgoulis, G., Agnelli, G., et al. (2021) Comparison of Antithrombotic Strategies in Patients with Cryp-togenic Stroke and Patent Foramen Ovale: An Updated Meta-Analysis. Cardiovascular Drugs and Therapy, 35, 987-993. https://doi.org/10.1007/s10557-020-07068-9
|
[42]
|
Homma, S., Sacco, R.L., Di Tullio, M.R., et al. (2002) Effect of Medical Treatment in Stroke Patients with Patent Foramen Ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation, 105, 2625-2631.
https://doi.org/10.1161/01.CIR.0000017498.88393.44
|
[43]
|
Shariat, A., Yaghoubi, E., Farazdaghi, M., et al. (2013) Comparison of Medical Treatments in Cryptogenic Stroke Patients with Patent Foramen Ovale: A Randomized Clinical Trial. Journal of Research in Medical Sciences, 18, 94-98.
|
[44]
|
Hart, R.G., Sharma, M., Mundl, H., et al. (2018) Riva-roxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. The New England Journal of Medicine, 378, 2191-2201. https://doi.org/10.1056/NEJMoa1802686
|
[45]
|
Diener, H.C., Sacco, R., Easton, J.D., et al. (2019) Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. The New England Journal of Medi-cine, 380, 1906-1917. https://doi.org/10.1056/NEJMoa1813959
|
[46]
|
Huang, W.Y., Ovbiagele, B., Lee, M. (2022) Oral Anticoagulants vs Antiplatelets in Cryptogenic Stroke with Potential Cardiac Emboli: Meta-Analysis. European Journal of Internal Medicine, 95, 44-49.
https://doi.org/10.1016/j.ejim.2021.08.002
|
[47]
|
Chen, S., Cai, D., Lai, Y., et al. (2022) Dabigatran versus Aspirin for Stroke Prevention after Cryptogenic Stroke with Patent Foramen Ovale: A Prospective Study. Clinical Neurology and Neurosurgery, 215, Article ID: 107189.
https://doi.org/10.1016/j.clineuro.2022.107189
|
[48]
|
Shen, Y., Nie, Q., Zhang, Y., et al. (2021) Treatment Strategies for Cryptogenic Stroke Patients with Patent Foramen Ovale: What Do We Choose? Neuropsychiatric Disease and Treatment, 17, 3205-3214.
https://doi.org/10.2147/NDT.S333930
|